0001193125-20-103126.txt : 20200514 0001193125-20-103126.hdr.sgml : 20200514 20200410083402 ACCESSION NUMBER: 0001193125-20-103126 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 CORRESP 1 filename1.htm CORRESP

Via EDGAR Submission

April 10, 2020

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

  Re:

Immunovant, Inc. (the “Company”)

      

Registration Statement on Form S-1 (File No. 333-237627)

Ladies and Gentlemen:

As representatives of the several underwriters of the Company’s proposed public offering of common stock, we hereby join the Company’s request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 9:00 a.m. (ET) on April 14, 2020, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

 

 

 

[Remainder of Page Intentionally Left Blank]

Very truly yours,

 

As Representatives of the several Underwriters

 

SVB LEERINK LLC

By:   /s/ Dan Dubin
  Name:  Dan Dubin
  Title:    Vice Chairman

 

UBS SECURITIES LLC

By:   /s/ Robin Tang
  Name:  Robin Tang
  Title:    Director
By:   /s/ James Raul Stahlke
  Name:  James Raul Stahlke
  Title:    Associate Director

 

SUNTRUST ROBINSON HUMPHREY, INC.

By:   /s/ Charles E. Mather
  Name:  Charles E. Mather
  Title:    Managing Director

 

 

 

 

 

[Signature Page to Acceleration Request]